• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad , March 6

Aurobindo Pharma Ltd (APL) has announced that it has received product approval (notice of compliance) from Health Canada for Citalopram Hydrobromide 20 mg and 40 mg tablets.

The tablets are indicated in the treatment of depressive disorders. The active pharmaceutical ingredient of this product is manufactured at unit 1 of the company. The formulation facility of the company is already approved by Health Canada.

Citalopram Hydrobromide tablets are a generic equivalent of Forest Laboratories' Celexa and it is from a class of medications called `selective serotonin reuptake inhibitors'.

In a press release here on Monday, the company said Citalopram Hydrobromide 20 mg and 40 mg is the first formulation approved in Canada. The company is already selling the product in the US market.

APL has established a subsidiary in Canada to serve the local market and has also filed a number of dossiers, the release said.

More Stories on : Announcements | Health | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Aurobindo's Citalopram gets Health Canada nod

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line